Efficacy and safety of VCEP-M for induction treatment of mixed phenotypic acute leukemia.

Authors:

Abstract
E18504 Background: Mixed phenotype acute leukemia (MPAL) is a rare subtype of acute leukemia, characterized by an aggressive behavior and a tendency towards resistance to therapy and overall poor outcome. The aim of the study is to evaluate the efficacy and toxicity of VCEP-M protocol. Methods: A retrospective study. We included patients diagnosed with mixed phenotypic acute leukemia at King Faisal Specialist Hospital and research Centre (based on WHO and EGIL criteria) from 2002-2014 treated with upfront VCEP-M Protocol. We excluded patients who are less than 15 years of age and patients treated outside our institution. Data were collected from our electronic tumor registry. Results: We included 19 patients who met the inclusion criteria. Baseline characterisitics are shown below. Ten patients were salvaged at Day 14 Bone marrow with Fludarabine 30mg/m2/d and cytarabine 2gm/m2/d (D1-5) (FA) chemotherapy. Complete remission (CR) rate at day 28 bone marrow was 95% (18 patients). Thirteen patients proceeded to allogenic stem cell transplantation (SCT). All 6 patients who had not had SCT died. Overall survival (OS) and disease free survival (DFS) at 5 years were 54% and 57% respectively. Treatment related toxicity were mainly sepsis (11 patients) and disseminated intravascular coagulation (DIC) (2 patients). There was no reported treatment related deaths. Conclusions: VCEP-M appears effective in the treatment of MPAL with a safe toxicity profile. All patients would likely benefit from SCT.